• Something wrong with this record ?

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension

N. Galiè, P. Jansa, T. Pulido, RN. Channick, M. Delcroix, HA. Ghofrani, FO. Le Brun, S. Mehta, L. Perchenet, LJ. Rubin, BKS. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki,

. 2017 ; 38 (15) : 1147-1155.

Language English Country Great Britain

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016710

Aims: The effect of macitentan on haemodynamic parameters and NT-proBNP levels was evaluated in pulmonary arterial hypertension (PAH) patients in the SERAPHIN study. Association between these parameters and disease progression, assessed by the primary endpoint (time to first morbidity/mortality event), was explored. Methods and results: Of the 742 randomized patients, 187 with right heart catheterization at baseline and month 6 participated in a haemodynamic sub-study. Prespecified endpoints included change from baseline to month 6 in cardiac index (CI), right atrial pressure (RAP), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), mixed-venous oxygen saturation, and NT-proBNP. Exploratory analyses examined associations between CI, RAP, and NT-proBNP and disease progression using the Kaplan-Meier method and Cox regression models. Macitentan improved CI, RAP, mPAP, PVR and NT-proBNP vs. placebo at month 6. Absolute levels of CI, RAP and NT-proBNP at baseline and month 6, but not their changes, were associated with morbidity/mortality events. Patients with CI > 2.5 L/min/m2, RAP < 8 mmHg, or NT-proBNP < 750 fmol/ml at month 6 had a lower risk of morbidity/mortality than those not meeting these thresholds (HR 0.49, 95% CL 0.28-0.86; HR 0.72, 95% CL 0.42-1.22; and HR 0.22, 95% CL 0.15-0.33, respectively). Conclusions: For all treatment groups, baseline and month 6 values of CI, RAP, and NT-proBNP, but not their changes, were associated with morbidity/mortality events, confirming their relevance in predicting disease progression in patients with PAH. By improving those parameters, macitentan increased the likelihood of reaching threshold values associated with lower risk of morbidity/mortality.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016710
003      
CZ-PrNML
005      
20180517141103.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehx025 $2 doi
035    __
$a (PubMed)28329315
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Galiè, Nazzareno $u Department of Experimental, Diagnostic and Specialty Medicine-DIMES, via Massarenti 9, Bologna 40138, Italy.
245    10
$a SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension / $c N. Galiè, P. Jansa, T. Pulido, RN. Channick, M. Delcroix, HA. Ghofrani, FO. Le Brun, S. Mehta, L. Perchenet, LJ. Rubin, BKS. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki,
520    9_
$a Aims: The effect of macitentan on haemodynamic parameters and NT-proBNP levels was evaluated in pulmonary arterial hypertension (PAH) patients in the SERAPHIN study. Association between these parameters and disease progression, assessed by the primary endpoint (time to first morbidity/mortality event), was explored. Methods and results: Of the 742 randomized patients, 187 with right heart catheterization at baseline and month 6 participated in a haemodynamic sub-study. Prespecified endpoints included change from baseline to month 6 in cardiac index (CI), right atrial pressure (RAP), mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), mixed-venous oxygen saturation, and NT-proBNP. Exploratory analyses examined associations between CI, RAP, and NT-proBNP and disease progression using the Kaplan-Meier method and Cox regression models. Macitentan improved CI, RAP, mPAP, PVR and NT-proBNP vs. placebo at month 6. Absolute levels of CI, RAP and NT-proBNP at baseline and month 6, but not their changes, were associated with morbidity/mortality events. Patients with CI > 2.5 L/min/m2, RAP < 8 mmHg, or NT-proBNP < 750 fmol/ml at month 6 had a lower risk of morbidity/mortality than those not meeting these thresholds (HR 0.49, 95% CL 0.28-0.86; HR 0.72, 95% CL 0.42-1.22; and HR 0.22, 95% CL 0.15-0.33, respectively). Conclusions: For all treatment groups, baseline and month 6 values of CI, RAP, and NT-proBNP, but not their changes, were associated with morbidity/mortality events, confirming their relevance in predicting disease progression in patients with PAH. By improving those parameters, macitentan increased the likelihood of reaching threshold values associated with lower risk of morbidity/mortality.
650    _2
$a srdeční katetrizace $7 D006328
650    _2
$a progrese nemoci $7 D018450
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a antagonisté endotelinového receptoru $x aplikace a dávkování $x škodlivé účinky $7 D065128
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x farmakoterapie $x mortalita $x patofyziologie $7 D006976
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a natriuretický peptid typu B $x metabolismus $7 D020097
650    _2
$a peptidové fragmenty $x metabolismus $7 D010446
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $7 D011743
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sulfonamidy $x aplikace a dávkování $x škodlivé účinky $7 D013449
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dysfunkce pravé srdeční komory $x mortalita $x patofyziologie $7 D018497
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jansa, Pavel $u Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech Republic.
700    1_
$a Pulido, Tomás $u Cardiopulmonary Department, Ignacio Chávez, National Heart Institute, Mexico City, Mexico.
700    1_
$a Channick, Richard N $u Pulmonary and Critical Care, Massachusetts General Hospital, Boston, MA, USA.
700    1_
$a Delcroix, Marion $u Department of Pneumology, Gasthuisberg University Hospital, Leuven, Belgium.
700    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, Member of the German Center of Lung Research (DZL), and Department of Medicine, Imperial College London, London, UK.
700    1_
$a Le Brun, Franck-Olivier $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Mehta, Sanjay $u Division of Respirology, Department of Medicine, London Health Sciences Centre, Victoria Hospital, Western University, London, ON, Canada.
700    1_
$a Perchenet, Loïc $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Rubin, Lewis J $u Division of Pulmonary and Critical Care Medicine, University of California, San Diego Medical School, San Diego, CA, USA.
700    1_
$a Sastry, B K S $u Department of Cardiology, CARE Hospitals, Hyderabad, India.
700    1_
$a Simonneau, Gérald $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM U-999, Le Kremlin-Bicêtre, France.
700    1_
$a Sitbon, Olivier $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM U-999, Le Kremlin-Bicêtre, France.
700    1_
$a Souza, Rogério $u Pulmonary Department, Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
700    1_
$a Torbicki, Adam $u Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Education, ECZ-Otwock, Poland.
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 38, č. 15 (2017), s. 1147-1155
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28329315 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180517141239 $b ABA008
999    __
$a ok $b bmc $g 1300334 $s 1013550
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 38 $c 15 $d 1147-1155 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options